Cargando…

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes

BACKGROUND: The 2017 Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) Clostridium (Clostridioides) difficile infection (CDI) guideline update recommended treatment with fidaxomicin or vancomycin for CDI. We aimed to examine outpatient CDI treatment ut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubberke, Erik R, Puckett, Justin T, Obi, Engels N, Kamal-Bahl, Sachin, Desai, Kaushal, Stuart, Bruce, Doshi, Jalpa A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578155/ https://www.ncbi.nlm.nih.gov/pubmed/36267250 http://dx.doi.org/10.1093/ofid/ofac435

Ejemplares similares

15. Real-World Changes in Clostridioides difficile infection (CDI) Treatment Utilization and Clinical Outcomes Associated with Updated 2017 IDSA Guidelines among Medicare Beneficiaries in the U.S
por: Dubberke, Erik R, et al.
Publicado: (2021)

Adoption and Trends in Uptake of Updated ICD-10 Codes for Clostridioides difficile—A Retrospective Observational Study
por: Deshpande, Abhishek, et al.
Publicado: (2022)

678. Changes in the Clostridioides difficile Infection (CDI) Treatment Pattern Pre-Post Clinical Guideline Update in 2021 and Variations across Hospitals
por: Dubberke, Erik R, et al.
Publicado: (2023)

The Clinical Burden of Clostridioides difficile in Ontario, Canada
por: Pereira, Jennifer A, et al.
Publicado: (2019)

Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection
por: Olsen, Margaret A, et al.
Publicado: (2023)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
por: Gonzales-Luna, Anne J, et al.
Publicado: (2021)

Influence of Diagnostic Method on Outcomes in Phase 3 Clinical Trials of Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: A Post Hoc Analysis of MODIFY I/II
por: Wilcox, Mark H, et al.
Publicado: (2019)

Updated Management Guidelines for Clostridioides difficile in Paediatrics
por: Gnocchi, Margherita, et al.
Publicado: (2020)

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial
por: Garey, Kevin W, et al.
Publicado: (2023)

Clostridioides difficile Enteritis in Patients Following Total Colectomy—a Rare but Genuine Clinical Entity
por: Ulrich, Robert J, et al.
Publicado: (2019)

A Risk Score to Predict Clostridioides difficile Infection
por: Aukes, Laurie, et al.
Publicado: (2021)

Propensity-Matched Cost of Clostridioides difficile Infection Overdiagnosis
por: Madden, Gregory R, et al.
Publicado: (2020)

Clostridioides difficile Infection: Clinical Practice and Health Outcomes in 6 Large Tertiary Hospitals in Eastern Australia
por: Stewart, Adam G, et al.
Publicado: (2023)

Community-Onset Clostridioides Difficile Infection in Hospitalized Patients in The Netherlands
por: Crobach, M J T, et al.
Publicado: (2019)

Pet Ownership Protects Against Recurrence of Clostridioides difficile Infection
por: Redding, Laurel E, et al.
Publicado: (2020)

Binary Toxin Expression by Clostridioides difficile Is Associated With Worse Disease
por: Young, Mary K, et al.
Publicado: (2022)

Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study
por: Wilcox, Mark H, et al.
Publicado: (2019)

Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

Patient Outcomes With Prevented vs Negative Clostridioides difficile Tests Using a Computerized Clinical Decision Support Tool
por: Madden, Gregory R, et al.
Publicado: (2020)

Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection
por: Alonso, Carolyn D, et al.
Publicado: (2021)

787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers
por: Garey, Kevin W, et al.
Publicado: (2020)

Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients
por: Johnson, Tanner M, et al.
Publicado: (2021)

Preservation of the Innate Immune Response to Clostridioides difficile Infection in Hospitalized Immunocompromised Patients
por: Banegas, Marcela, et al.
Publicado: (2023)

Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
por: Chaar, Abdelkader, et al.
Publicado: (2021)

Treatment of Clostridioides difficile infection: from guidelines to clinical practice
por: Merino, Esperanza, et al.
Publicado: (2022)

Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial( )
por: Garey, Kevin W, et al.
Publicado: (2022)

Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains
por: Endres, Bradley T, et al.
Publicado: (2019)

Persistent Systemic Microbial Translocation, Inflammation, and Intestinal Damage During Clostridioides difficile Infection
por: Oliva, Alessandra, et al.
Publicado: (2019)

The Impact of Infection Versus Colonization on Clostridioides difficile Environmental Contamination in Hospitalized Patients With Diarrhea
por: Warren, Bobby G, et al.
Publicado: (2022)

Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
por: de la Villa, Sofía, et al.
Publicado: (2023)

Clostridioides difficile Binary Toxin Binding Component Increases Virulence in a Hamster Model
por: Simpson, Morgan, et al.
Publicado: (2023)

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

Clostridioides difficile therapeutics: guidelines and beyond
por: Orenstein, Robert, et al.
Publicado: (2019)

P1695: REAL-WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-GEMOX IN THE RELAPSED/REFRACTORY SETTING
por: Garg, Mahek, et al.
Publicado: (2023)

98. Outcomes of Clinical Decision Support for Outpatient Management of Clostridioides difficile Infection
por: Wu, Tiffany, et al.
Publicado: (2021)

GABAergic but not Antidepressant Medications Increase Risk for Clostridioides difficile Infection in a National Cohort of Veterans
por: Lalani, Falak, et al.
Publicado: (2020)

Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model
por: Budi, Noah D, et al.
Publicado: (2022)

An Update on Clostridioides difficile Binary Toxin
por: Martínez-Meléndez, Adrián, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k62cbakmhjlgbb1474l5d38nl2